Pandion Therapeutics, Inc.
DelistedCIK 1807901fmd_1JTM9F9B3DH44K94YMJV2C9S6CManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2020, 8 periods
| Line item | FY2019 | FY2020 |
|---|---|---|
| Total revenues | 1 | 9 |
| Research and development | 18 | 34 |
| Total operating expenses | 23 | 47 |
| Operating income | (22) | (38) |
| Interest expense | 0 | 0 |
| Interest and investment income | 0 | 0 |
| Income tax expense | 0 | 0 |
| Net income | (22) | (38) |
| Net income to common shareholders | (26) | (43) |